Omega Therapeutics, a preclinical biotech developing gene therapies for cancer and other diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Omega Therapeutics aims to use its proprietary OMEGA Epigenomic Programming platform to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics. Its pipeline consists of preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases. The company has conducted in vivo preclinical studies in hepatocellular carcinoma, non-small cell lung cancer, and acute respiratory distress syndrome.
The Cambridge, MA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol OMGA. Omega Therapeutics filed confidentially on May 10, 2021. Goldman Sachs, Jefferies, Piper Sandler, and Wedbush PacGrow are the joint bookrunners on the deal. No pricing terms were disclosed.
